37142 Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment 1 in the

application kit.

AR–1—Human Subjects Requirements

AR–2—Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–9—Paperwork Reduction Act

Requirements

AR–10—Smoke-Free Workplace

Requirements

AR–11—Healthy People 2010

AR–12—Lobbying Restrictions

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 301 of the Public Health Service

Act, [42 U.S.C. section 241], as

amended. The Catalog of Federal

Domestic Assistance number is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

are available through the CDC homepage

on the Internet at: http://www.cdc.gov.

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888 472–6874). You will be asked to

leave your name and address and will

be instructed to identify the program

announcement number (00010).

If you have questions after reviewing

the contents of all the documents,

business management assistance may be

obtained from: Sonia Rowell, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Announcement 00010,

Centers for Disease Control and

Prevention, Room 3000, 2920

Brandywine Road, Atlanta, GA 30341–

4146, Telephone: (770) 488–2724, email

address: svp1@cdc.gov

For program technical assistance,

contact: Pamela Meyer, Epidemiologist,

Air Pollution and Respiratory Health

Branch, National Center for

Environmental Health, Centers for

Disease Control and Prevention, 1600

Clifton Road, NE, Mailstop E–17,

Atlanta GA 30333, telephone: (404)

639–2545, email address:

pmeyer@cdc.gov

Dated: June 7, 2000.

Henry S. Cassell III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–14830 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00097]

Uniform Population-Based Approach

to Case Ascertainment, Typology,

Surveillance, and Research on

Childhood Diabetes; Notice of

Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program to develop a multi-center and

uniform population-based approach to

case ascertainment, typology,

surveillance, and research on childhood

diabetes (diagnosis before the age of 20

years). This program addresses the

‘‘Healthy People 2010’’ focus area of

Diabetes. For the conference copy of

‘‘Healthy People 2010,’’ visit the

internet site: <http://

www.healthypeople>. In view of the

importance of racial and ethnic health

disparity issues, the purpose of the

program is to use a uniform multi-center

approach in diverse populations for

multiple purposes:

1. Using existing data of known

prevalent cases of childhood diabetes,

develop a uniform typology of the

prevalent cases, obtain type-specific

prevalence estimates, and describe

characteristics of the different types of

childhood diabetes;

2. Based on the extensive collection of

new cases of childhood diabetes,

develop a uniform typology of the

incident cases, obtain accurate and

precise population-based estimates of

the type-specific incidence and secular

trends of new cases, and describe the

characteristics of the different types of

childhood diabetes;

3. Develop a uniform approach to

follow incident cases of childhood

diabetes to ascertain changes in

typology, characteristics and outcomes,

and to maintain a ‘‘pool’’ of incident

cases of childhood diabetes.

Characterization of types of childhood

diabetes should include a description of

potential risk factors (including family

history, maternal diabetes, race/

ethnicity, sex, weight and height, birthweight, etc), other characteristics

(including presence of acanthosis

nigricans, symptoms and circumstances

at or preceding diagnosis, treatment and

response to treatment, HbA1c, lipids,

and blood pressure levels, etc), potential

laboratory measurements (C-peptide and

insulin levels, immunological markers,

etc), potential complications (including

microalbuminuria, hypertension,

retinopathy, neuropathy, infections,

etc), and quality of medical care

(including screening frequencies for

HbA1c, lipid profiles,

microalbuminuria, retinal and foot

examinations, blood pressure checks,

nutrition counseling, rates of

hospitalization for complications, etc).

This collaborative program will

consist of two phases. Phase I (12

months)—Planning, developing

networks of care providers and other

partnerships, and collaboration on the

development of the protocol and

Institutional Review Board clearances.

Phase II (48 months)—Data collection,

monitoring, analyzes, and collaborative

reporting of the results, on a yearly

basis.

B. Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and by governments and

their agencies; that is, universities,

colleges, research institutions, hospitals,

other public and private nonprofit

organizations, State and local

governments or their bona fide agents,

and federally recognized Indian tribal

governments, Indian tribes, or Indian

tribal organizations.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $500,000 is available

in FY 2000 to fund approximately 2 to

3 awards. It is expected that the average

award will be $200,000 ranging from

$150,000 to $250,000. It is anticipated

that additional funds may be available

in FY 2001–2004 to increase the average

award to approximately $500,000 in

Years 2–5, ranging from $400,000 to

$600,000. It is expected that the awards

will begin on or about September 30,

2000, and will be made for a 12-month

budget period within a project period of

up to 5 years.

Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices 37143

Funding Estimates May Change

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

Use of Funds

Funds are awarded for a specifically

defined purpose and must be targeted

for implementation and management of

the project. Funds can support

personnel, activities directly related to

the project, and the purchase of software

for data collection, analysis, and project

management and evaluation purposes.

Prohibited Uses: Cooperative

agreement funds under this program

announcement cannot be used for (1)

construction, (2) renovation, (3) the

purchase or lease of passenger vehicles

or vans, (4) to supplant non-federal

funds that would otherwise be made

available for this purpose, or (5) cost of

regular patient care.

Funding Priority

In making awards, priority

consideration will be given as follows.

Due to the high prevalence of type 2

diabetes in American Indian children,

funding priority will be given to at least

one center which will have access to

American Indian populations. In

addition, approved applications may

also be ranked and funded based on

populations with racial/ethnic and

socio-economic diversity to achieve

geographic, socio-economic and racial/

ethnic representation of the U.S.

population, and a minimum mix of the

different types of childhood diabetes (at

least 20% type 2).

Minimum Requirement

Applications for the development of a

multi-center and uniform populationbased approach to case ascertainment,

typology, surveillance, and research on

childhood diabetes in diverse

populations require access to

information on large numbers of

children with diabetes (minimum of 50

incident cases per year) and their

referent populations (minimum of

300,000 children under the age of 20)

with racial/ethnic and socio-economic

diversity, including under-insured.

Institutions may apply as a single

entity or in collaborative partnership or

network(s). However, only one

institution will be named as the

recipient of funds in a partnership/

network.

Eligibility characteristics for review

must be clearly specified with

appropriate documentation in the

Application Requirements section of

your application (see Application

Content).

D. Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under 1. (Recipient Activities), and CDC

will be responsible for the activities

listed under 2. (CDC Activities).

1. Recipient Activities

a. Establish and sustain networks or

partnerships with health care providers

and health care systems who have

access to information on cases of

childhood diabetes. Collaborate with

other health organizations, community

groups, State Health Department,

Diabetes Control Programs etc., as

necessary to accomplish program

activities.

b. Establish a Steering Committee that

will be the primary governing body of

the study and will be comprised of each

of the Principal Investigators from each

center. The Steering Committee will

have primary responsibility for

developing manual(s) of operations and

common study protocols, submitting the

protocols for CDC and other

Institutional Review Boards, and

coordinating resolution of Institutional

Review Board issues, facilitating the

conduct of the study and on-going data

collection, analyses, and reporting of

study results.

c. Participate in the methodology and

protocol development, on-going data

collection and follow-up, quality

control, data analysis and interpretation,

the preparation of peer-reviewed

publications, and presentation of

findings.

d. Work cooperatively with the other

Centers, and agree to follow the

common protocol(s) and manual(s) of

operations developed in Phase I of the

study by the Steering Committee.

e. Maintain an effective and adequate

management and staffing plan. Staff

should have the education, background,

and experience to successfully conduct

the activities proposed in this

application. As a part of the application,

the existing staff and all proposed

positions should to be included.

2. CDC Activities

a. Support the recipients’ activities by

collaborating and providing scientific

and public health consultation and

assistance in the development of

activities related to the cooperative

agreement and coordination sharing.

b. Assist in facilitating

communication among recipients

development of common multi-center

protocol(s), quality control, interim data

monitoring, data analysis,

interpretation, reporting, and

coordination.

c. Assist in the development of a

research protocol for IRB review by all

cooperating institutions participating in

the research project, including CDC IRB.

d. Serve as a consultant to the

Steering Committee.

E. Application Content

Competing Applications

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections of the

announcement and the Errata Sheet in

the application to develop the

application content. Your application

will be evaluated on the criteria listed,

so it is important to follow them in

laying out your program plan.

The outcome of this program should

provide reliable estimates of the

prevalence, incidence and secular

trends of the different types of

childhood diabetes, and should enable

the development of case definition and

characterization at diagnosis and followup of the different types of childhood

diabetes. More specifically, the

following questions should be

answered:

1. Using existing data of known

prevalent cases of childhood diabetes,

how could prevalent cases be classified,

and what are the type-specific

prevalence estimates and the

characteristics (including medical care

received) of the different types of

childhood diabetes?

2. Based on the extensive collection of

new data, how could incident cases of

childhood diabetes be classified, and

what are the accurate and precise

population-based estimates of the typespecific incidence and secular trends,

and the characteristics (including

medical care received) of the different

types of diabetes.

3. How could incident cases of

childhood diabetes be followed in a

uniform approach, and what are their

characteristics, outcomes and quality of

care at follow-up? How could a ‘‘pool’’

of incident cases be maintained for

studying secular trends in incidence

and factors associated with causation?

Emphasis should be on rigorous

scientific approaches and

methodologies that should yield access

to populations of diverse ethnicity,

socioeconomic status and insurance

coverage, produce reliable populationbased estimates that should adequately

address ascertainment biases, and

should assure sustainability to provide

data for secular trend assessment and

follow-up for the different types of

childhood diabetes.

37144 Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices

Each applicant must describe the

proposed populations, the methodology

and study designs that best address the

objectives of this program, as well as the

networks and partnerships that should

help achieve these objectives.

Applications should propose a uniform

and multi-center approach, which

considers the problem of racial/ethnic

health disparities.

Collaborative protocol(s) to study the

above questions should be developed by

a Steering Committee composed of the

recipients. The collaborative study

protocol(s) should move into the

implementation stage with the

concurrence of the Steering Committee.

It is not the intent of this Program

Announcement to solicit elaborately

detailed research plans for the above

proposed collaborative project because

the final protocol(s) should be

collaboratively developed by the

investigators during the planning phase

(Phase I).

Eligibility characteristics must be

clearly specified with appropriate

documentation in the Application

Requirements section of your

application.

The application narrative must

include the following sections in the

order presented below:

a. Description and rationale of (a) the

population source (including size, age,

ethnicity, medical insurance status,

socio-economic status, geographic), and

b. The partnership/network(s) which

will provide access to information on

the cases within this population source

(not to exceed 5 pages).

(1) When describing the population

source, indicate the degree to which

racial and ethnic minority and socioeconomically disadvantaged

populations are included, and how the

population is sufficiently typical of

children with diabetes around the

country or accurately represents special

groups of children with the disease.

(2) When describing the partnership/

network(s), detail the various types of

providers which are included.

(3) Describe why and to what extent

different types of childhood diabetes

will be captured, and detail all (hospital

and non hospital) data sources that will

be used.

(4) Discuss how the population size

(denominator) will be ascertained for

estimation of incidence and secular

trends over the 5 years of study.

(5) Discuss how the population-based

estimates will be tested.

(6) Discuss how the networks/

partnerships will be sustained over a

long term to allow for trend estimates,

follow-up, and maintenance of a ‘‘pool’’

of incident cases. Describe potential

provider or patient incentives that may

be used to assure sustainability and

follow-up.

(7) Include a discussion of the

rationale, benefits and problems that

may be faced in relation to the selected

population source and partnership/

network(s) developed, and describe the

extent to which the choice of the

population source and the networks/

partnerships is scientifically sound,

realistic, and likely to provide reliable

population-based estimates and secular

trends for childhood diabetes.

c. Methodology: Case ascertainment,

typology characterization, and followup of (a) the prevalent cases, and (b) the

incident cases (not to exceed 5 pages).

(1) Describe why and how the

previously collected data on prevalent

cases of childhood diabetes will be

available, and include a description of

the case characteristics (including

number, age, sex, ethnicity, medical

insurance status or socio-economic

status, geographic).

(2) Describe why and how

information on a large number of

incident cases of childhood diabetes

(≥50 a year) will be available for each

year of the study, and will approach

complete ascertainment of diagnosed

childhood diabetes in the population

source. Describe various strategies to:

(3) Ascertain the prevalent and

incident cases.

(4) Collect information to type and

characterize the different prevalent and

incident types of childhood diabetes.

(5) Follow the incident cases for

characterization and maintenance of a

‘‘pool’’ of incident cases.

(6) Address potential for misclassifications at baseline for prevalent

and incident cases, and changes at

follow-up for the incident cases, and

other biases.

Note that characterization for (a) and

(b) should include health care received,

potential outcomes, and risk factor

levels, and should use low-cost and

realistic methods. Note that all proposed

approaches should discuss cost

implications (cost per case identified

and cost per case maintained).

Also, note that emphasis should be on

accurate estimation of incidence (to

approach complete ascertainment of

newly diagnosed childhood diabetes), as

opposed to estimation of prevalence,

which is based on previously collected

information. It is not anticipated in this

announcement that screening programs

will be initiated to approach complete

ascertainment of incidence, but if such

screening programs are independently

implemented, they may constitute a

valuable addition to the present study.

d. Standardization across sites (not to

exceed 1 page):

(1) Discuss how methods for

identification and classification of

childhood diabetes cases could be

standardized across sites and over the

study period;

(2) Discuss how the design and the

standardization will ensure that

maximum and wide use of the system

will be made and sustained.

e. Background and experience of the

principal investigator, co-investigators,

and the applying institution,

organization, or agency (not to exceed 3

pages).

(1) Describe the educational and

professional background of the principal

investigator.

(2) Document the relevant experience

of the principal investigator and

qualifications of the applying

institution, organization, or agency for

carrying out epidemiological or

surveillance research in chronic disease

(including access to computerized data

systems and other relevant resources)

and collaborative, multi-center research

projects.

(3) Describe existing partnership/

network(s) with other agencies/

organizations/institutions or others

(specifically, involvement in existing or

past registries of type 1 diabetes or other

similar systems designed for disease

monitoring), and with supportive State

Health Departments, Diabetes Control

Programs, or other relevant

organizations, for the purpose of

relevant medical research.

(4) Attach evidence of collaborations

and partnerships, specifying the

commitment of the parties involved in

partnership/networking(s), and provide

details, including the terms of access to

data and to populations and any

specified limits to collaboration.

(5) Provide a brief description of how

the project will be organized, and

indicate the proposed staffing plan and

expertise, and the time line.

f. Human Subjects. Address the

requirements of Title 45 CFR 46 for the

protection of human subjects, and detail

the degree to which CDC Policy

requirements regarding the inclusion of

women, ethnic, and racial groups in the

proposed research are met. This

includes:

(1) The proposed plan for the

inclusion of both sexes and racial and

ethnic minority populations for

appropriate representation.

(2) The proposed justification when

representation is limited or absent.

(3) A statement as to whether the

design of the study is adequate to

measure differences when warranted.

Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices 37145

(4) A statement as to whether the

plans for recruitment and outreach for

study participants include the process

of establishing partnerships with

community(ies) and recognition of

mutual benefits.

g. Budget and budget justification (not

to exceed 5 pages).

Provide a detailed, line-item budget

with justification that demonstrates the

request is consistent with the purpose

and objectives of this program. The

budget for Phase I of the study should

be clearly delineated. Budgets should

allow for approximately three persons,

including the principal investigator, to

attend Steering Committee and

Subcommittee meetings. The detailed

budget for Phase I should be planned

and developed to assure that the project

protocol may be written within the first

nine months utilizing Steering

Committee meetings and teleconference

calls by the Steering.

Typing and Mailing

All pages must be clearly numbered

and a complete index to the application

and its appendixes must be included.

Do not bind, staple, or paper clip any

pages of any copy of the application,

including appendixes. Do not include

any bound documents (e.g., pamphlets

or other publications) in the

appendixes. Do not include cardboard,

plastic, or other page separators between

the sections. The entire application

must be typewritten, single-spaced, and

in unreduced type (12-point fonts) on

81⁄2′′ x 11′′ white paper, with at least 1′′

margins, including headers and footers,

and printed on one side only.

F. Submission and Deadline

Letter of Intent (LOI)

Your letter of intent should include

the following information: The name

and address of the applying institution,

telephone number of the contact person,

and the program announcement

number.

The letter of intent must be submitted

on or before, June 30, 2000,to the Grants

Management Specialist, as identified in

the ‘‘Where to Obtain Additional

Information’’ section of this

announcement.

Application

Submit the original and five copies of

form PHS 398. Forms are available at

the following Internet address: http://

www.cdc.gov/od/pgo/forminfo.htm or

in the application kit. Submit the

application on or before July 21,2000, to

the Grants Management Specialist

identified in the section ‘‘Where to

Obtain Additional Information.’’

Deadline: Applications shall be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for orderly

processing. (Applicants must request a

legibly dated U.S. Postal Service

postmark or obtain a legibly dated

receipt from a commercial carrier or

U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

Late Applications: Applications

which do not meet the criteria in (a) or

(b) above are considered late

applications, will not be considered,

and will be returned to the applicant.

G. Evaluation Criteria (Total 100

Points)

Each application will be evaluated

individually against the following

criteria by an independent review group

appointed by CDC.

1. Description and rationale for the

population and partnership/network(s)

(25 points):

a. The extent to which (1) the

population is described, (2) the

rationale, benefits and problems that

may be faced in relation to the

population are discussed, and (3) the

approach selected is scientifically

sound, realistic, and likely to provide

reliable population-based estimates and

characterization of the different types of

childhood diabetes. In particular, the

extent to which data sources other than

hospitalization data will be available.

b. The extent to which (1) the

partnership/network(s) is described, (2)

the rationale, benefits and problems that

may be faced in relation to the

partnership/network(s) are discussed,

and (3) the network/partnership(s)

selected are scientifically sound,

realistic, and likely to provide reliable

population-based estimates and

characterization of the different types of

childhood diabetes. In particular, the

extent to which different types and

sources of providers are available.

c. The degree to which (1) racial/

ethnic minority and socio-economically

disadvantaged populations and both

sexes are included, (2) the population is

sufficiently typical of children with

diabetes around the country or

accurately represents special groups of

children with the disease, and (3)

different types of childhood diabetes

will be captured.

d. The extent to which the

ascertainment of the population source

and testing of the population-based

estimates are scientifically sound,

realistic, and likely to provide reliable

and accurate population-based estimates

and secular trends for childhood

diabetes.

e. The extent to which the population

and partnership/network(s) will be

sustained over the study duration, and

will allow for secular trends assessment,

follow-up of incident cases, and

maintenance of a ‘‘pool’’ of incident

cases.

2. Rational for case ascertainment,

typology, and characterization of

prevalent cases (15 points):

a. The extent to which previously

collected data on prevalent cases of

childhood diabetes are described, and

the size, characteristics, quality, and

accessibility of this information.

b. The extent to which various

strategies are described, and are sound,

realistic, and feasible for case

ascertainment.

c. The extent to which various

strategies are described, and are sound,

realistic, and feasible for collection of

information to type and characterize the

different types of childhood diabetes,

and the extent to which characterization

includes health care received, potential

outcomes, and risk factor levels.

d. The extent to which various

strategies are described, and are sound,

realistic, and feasible for assessment of

potential misclassifications, and other

biases.

e. The extent to which low-cost and

realistic methods are used, and cost

implications are discussed (cost per case

identified).

3. Rationale for the methodology, case

ascertainment, typology,

characterization, and follow-up of

incident cases (25 points).

a. The extent to which information on

a large number of incident cases of

childhood diabetes (≥50 a year) is

available and described, and will

approach complete ascertainment of

diagnosed childhood diabetes in the

population source.

b. The extent to which various

strategies are described and are realistic,

feasible, and sustainable over 5 years for

ascertainment of incident cases.

c. The extent to which (1) various

strategies are described and are realistic,

feasible, and sustainable over 5 years for

collection of information to type and

characterize the difference types of

childhood diabetes, (2) characterization

includes health care received, potential

outcomes, and risk factor levels, and (3)

potential mis-classifications at baseline,

and changes at follow-up, and other

biases are assessed.

d. The extent to which various

strategies are described and are realistic,

feasible, and sustainable over 5 years for

follow-up of incident cases for

37146 Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices

characterization, typology and

maintenance of a ‘‘pool’’ of incident

cases.

e. The extent to which low-cost and

realistic methods are used, and cost

implications (cost per case identified

and cost per maintained) are discussed.

4. Standardization across sites (15

points):

a. The extent to which the proposed

approach to childhood diabetes research

is specific, realistic, time-phased, and

suitable for development into a

collaborative, multi-center study

protocol.

b. The extent to which the applicant

presents a detailed operational plan for

initiating and conducting the project

that clearly and appropriately addresses

all Recipient Activities.

c. The extent to which applicant

describes collaborations with other sites

during the various phases of the project,

and shows commitment to implement a

standardized, multi-center, collaborative

approach.

5. Background and Experience of the

Principal Investigator and of the

Applying Institution, Organization, or

Agency (20 points):

a. The educational and professional

background of the principal

investigator, and the relevant experience

of the principal investigator and

qualifications of the applying

institution, organization, or agency for

carrying on epidemiological or

surveillance research in chronic

diseases (including access to

computerized data systems and other

relevant resources) or multi-center

research projects.

b. Existence of partnership/network(s)

with other agencies/organizations/

institutions or others (specifically,

involvement in existing or past

registries of type 1 diabetes or other

similar systems designed for disease

monitoring), and with supportive State

Health Departments, Diabetes Control

Programs, or other relevant

organizations, for the purpose of

relevant medical research. Evidence that

commitment of the parties involved in

partnership/networking for this specific

project is provided, including the terms

of access to data and to populations, and

any specified limits to collaboration for

the purposes of this project.

c. The extent to which a brief

description is provided on how the

project will be organized, what the time

line and the proposed staffing plan will

be, and the extent to which the

applicant clearly identifies specific

assigned responsibilities and time

commitment of all key professional

personnel.

6. Human subjects (Not scored) Does

the application adequately address the

requirements of Title 45 CFR Part 46 for

the protection of human subjects? The

degree to which the applicant has met

the CDC Policy requirements regarding

the inclusion of women, ethnic, and

racial groups in the proposed research.

This includes: (a) the proposed plan for

the inclusion of both sexes and racial

and ethnic minority populations for

appropriate representation, (b) the

proposed justification when

representation is limited or absent, (c) a

statement as to whether the design of

the study is adequate to measure

differences when warranted, (d) a

statement as to whether the plans for

recruitment and outreach for study

participants include the process of

establishing partnerships with

community(ies) and recognition of

mutual benefits.

7. Budget and Budget Justification

(Not scored): The extent to which the

budget is reasonable and consistent with

the purpose and objectives of this

program; and specification and

discussion of cost per case identified,

cost per case maintained, and cost per

case type-classified.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with an original plus

two copies of the following:

1. Progress reports (semiannual);

2. Financial status report, no more

than 90 days after the end of the budget

period; and

3. Final financial and performance

reports, no more than 90 days after the

end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I in the

application kit.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–7 Executive Order 12372 Review

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–15 Proof of Non-Profit Status

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

sections 301(a) and 317(k)(2) [42 U.S.C.

241(a) and 247b(k)(2)] of the Public

Health Service Act, as amended. The

Catalog of Federal Domestic Assistance

number is 93.988.

J. Where To Obtain Additional

Information

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888–472–6874). You will be asked to

leave you name and address and will be

instructed to identify the

Announcement number of interest.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Barry

L. Copeland, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office,

Announcement #00097, Centers for

Disease Control and Prevention, Room

3000, 2920 Brandywine Road, Atlanta,

GA 30341–4146, Telephone number

(770) 488–2762, Email address

bjc8@cdc.gov.

This and other CDC announcements

can be found on the CDC homepage

internet address: http://www.cdc.gov

See Attachment II for background on the

program. For program technical

assistance, contact: Anne FagotCampagna, Division of Diabetes

Translation, Centers for Disease Control

and Prevention, 4770 Buford HWY, NE,

Mailstop K–68, Atlanta GA, 30341,

telephone number (770) 488–1053 (or

–1069), Email address adf8@cdc.gov.

Dated: June 6, 2000.

Henry S. Cassel, III,

Deputy Director, Procurement and Grants

Office, Center for Disease Control and

Prevention (CDC).

[FR Doc. 00–14829 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00069]

Initiatives to Develop and Implement

Programs to Enhance Epilepsy Public

Awareness and Partnership,

Education, and Communication; Notice

of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the